Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Share Price Passes Above Two Hundred Day Moving Average – What’s Next?

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)’s share price passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $42.43 and traded as high as $46.28. Global X Genomics & Biotechnology ETF shares last traded at $46.24, with a volume of 14,239 shares traded.

Global X Genomics & Biotechnology ETF Stock Up 0.2%

The company has a market cap of $50.40 million, a PE ratio of -19.76 and a beta of 1.22. The stock has a 50-day simple moving average of $47.30 and a 200 day simple moving average of $42.43.

Global X Genomics & Biotechnology ETF Dividend Announcement

The business also recently announced a dividend, which was paid on Wednesday, January 7th. Shareholders of record on Tuesday, December 30th were given a $0.5912 dividend. The ex-dividend date of this dividend was Tuesday, December 30th. This represents a yield of 259.0%. Global X Genomics & Biotechnology ETF’s dividend payout ratio is presently -26.50%.

Institutional Investors Weigh In On Global X Genomics & Biotechnology ETF

A number of institutional investors have recently made changes to their positions in the stock. IFP Advisors Inc lifted its holdings in shares of Global X Genomics & Biotechnology ETF by 20.8% in the 3rd quarter. IFP Advisors Inc now owns 2,835 shares of the company’s stock worth $110,000 after acquiring an additional 489 shares during the last quarter. Atria Investments Inc increased its holdings in Global X Genomics & Biotechnology ETF by 12.6% in the 2nd quarter. Atria Investments Inc now owns 18,520 shares of the company’s stock valued at $156,000 after purchasing an additional 2,073 shares during the last quarter. Smartleaf Asset Management LLC raised its position in Global X Genomics & Biotechnology ETF by 30.9% in the second quarter. Smartleaf Asset Management LLC now owns 19,548 shares of the company’s stock valued at $164,000 after purchasing an additional 4,615 shares during the period. Creative Financial Designs Inc. ADV raised its position in Global X Genomics & Biotechnology ETF by 86.7% in the second quarter. Creative Financial Designs Inc. ADV now owns 22,301 shares of the company’s stock valued at $188,000 after purchasing an additional 10,358 shares during the period. Finally, Sei Investments Co. lifted its stake in Global X Genomics & Biotechnology ETF by 110.4% during the second quarter. Sei Investments Co. now owns 23,073 shares of the company’s stock worth $194,000 after purchasing an additional 12,105 shares in the last quarter. 56.95% of the stock is currently owned by institutional investors and hedge funds.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.